title: Antioxidant and antithrombotic therapies for diabetic kidney disease.
abstract: With an increasing incidence, diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease and end-stage renal disease, and conventional therapies did not change this situation. This study intended to review and analyze the antioxidant and antithrombotic treatments of DKD for seeking novel therapeutic strategies. Relevant articles involved with antioxidant and antithrombotic treatments in DKD were retrieved and analyzed via systematic assessment. Meta-analysis showed that pancreatic kallikrein definitely reduced glycated hemoglobin in DKD patients (mean difference, 0.36%; 95% confidence interval, 0.08% to 0.63%; P = .01). Apart from the classic agents such as aspirin, novel drugs such as pancreatic kallikrein, sulodexide, and especially the traditional Chinese medicine including Tripterygium wilfordii and lumbrukinase, exert beneficial effects in DKD patients. Antioxidant and antithrombotic treatments are beneficial for DKD patients and represent promising therapeutic strategies in the future.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Yan
authors.forename: Baoqin
authors.initials: B
authors.lastname: Zhou
authors.forename: Yunfeng
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Nephrology, Second Affiliated Hospital, Nanchang University, Nanchang, China. gaosixu@163.com.
authors.forename: Gaosi
authors.initials: G
authors.lastname: Xu
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy*; D010450:Endopeptidases / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006801:Humans; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*; D020840:Tissue Kallikreins / Q000627:therapeutic use; D029757:Tripterygium
chemical_list: D000975:Antioxidants; D001241:Aspirin; D010450:Endopeptidases; D005343:Fibrinolytic Agents; D006442:Glycated Hemoglobin; D006025:Glycosaminoglycans; D028321:Plant Preparations; D020840:Tissue Kallikreins; C517652:hemoglobin A1c protein, human; C007858:glucuronyl glucosamine glycan sulfate; C083421:lumbrokinase